美国 · SEC FORM 4
RHYTHM PHARMACEUTICALS, INC.
RYTM · Nasdaq · CIK 0001649904 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
40 同一窗口内观察到的 Form 4 交易行
22 sales · 18 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 6 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2021-03-30 · Meeker David P.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 10,767,698
- 上期报告
- 10,287,811
- 日均成交量
- 761,706
- 回补天数
- 14.1
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2021-03-30 | Meeker David P | 买入 (P) | Common Stock | 10,000 | USD 20.17 | USD 201,700 | SEC 申报 ↗ |
Form 4 申报证据
101 transaction lines in the latest 365-day window; 487 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Meeker David P | 卖出 (S) | Common Stock | 50,000 | USD 102.67 | USD 5,133,560 | SEC 申报 ↗ |
| 2026-09-14 | Meeker David P | 期权行权／转换 (M) | Common Stock | 50,000 | USD 6.05 | USD 302,500 | SEC 申报 ↗ |
| 2026-08-31 | Smith Hunter C | 卖出 (S) | Common Stock | 62,774 | USD 105.46 | USD 6,619,896 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Meeker David P | 卖出 (S) | Common Stock | 50,000 | USD 102.67 | USD 5,133,560 | SEC 申报 ↗ |
| 2026-09-14 | Meeker David P | 期权行权／转换 (M) | Common Stock | 50,000 | USD 6.05 | USD 302,500 | SEC 申报 ↗ |
| 2026-08-31 | Smith Hunter C | 卖出 (S) | Common Stock | 62,774 | USD 105.46 | USD 6,619,896 | SEC 申报 ↗ |
| 2026-08-31 | Smith Hunter C | 期权行权／转换 (M) | Common Stock | 57,187 | USD 25.79 | USD 1,474,853 | SEC 申报 ↗ |
| 2026-08-13 | Shulman Joseph | 卖出 (S) | Common Stock | 5,079 | USD 119.75 | USD 608,210 | SEC 申报 ↗ |
| 2026-08-13 | Shulman Joseph | 期权行权／转换 (M) | Common Stock | 2,024 | USD 6.80 | USD 13,763 | SEC 申报 ↗ |
| 2026-08-13 | Garfield Alastair | 卖出 (S) | Common Stock | 7,763 | USD 117.57 | USD 912,697 | SEC 申报 ↗ |
| 2026-08-13 | Lee Jennifer Kayden | 卖出 (S) | Common Stock | 75,834 | USD 117.38 | USD 8,901,395 | SEC 申报 ↗ |
| 2026-08-13 | Lee Jennifer Kayden | 期权行权／转换 (M) | Common Stock | 56,601 | USD 17.62 | USD 997,037 | SEC 申报 ↗ |
| 2026-08-12 | Mazabraud Yann | 卖出 (S) | Common Stock | 57,000 | USD 116.15 | USD 6,620,591 | SEC 申报 ↗ |
| 2026-08-12 | Mazabraud Yann | 期权行权／转换 (M) | Common Stock | 46,625 | USD 6.80 | USD 317,050 | SEC 申报 ↗ |
| 2026-07-01 | Garfield Alastair | 期权行权／转换 (M) | Common Stock | 4,445 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-01 | Garfield Alastair | 代扣税 (F) | Common Stock | 2,150 | USD 110.41 | USD 237,382 | SEC 申报 ↗ |
| 2026-06-23 | TETRAULT LYNN A. | 期权行权／转换 (M) | Common Stock | 4,712 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-23 | MCGIRR DAVID W J | 期权行权／转换 (M) | Common Stock | 4,712 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-23 | JEAN CHRISTOPHE | 期权行权／转换 (M) | Common Stock | 4,712 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-23 | GOOD JENNIFER L | 期权行权／转换 (M) | Common Stock | 4,712 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-23 | Arbuckle Stuart A | 期权行权／转换 (M) | Common Stock | 4,712 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-22 | TETRAULT LYNN A. | 卖出 (S) | Common Stock | 37,000 | USD 100.32 | USD 3,711,840 | SEC 申报 ↗ |
| 2026-06-22 | TETRAULT LYNN A. | 期权行权／转换 (M) | Common Stock | 37,000 | USD 28.27 | USD 1,045,990 | SEC 申报 ↗ |
| 2026-05-18 | Smith Hunter C | 期权行权／转换 (M) | Common Stock | 3,000 | USD 17.87 | USD 53,610 | SEC 申报 ↗ |
| 2026-05-15 | German Christopher Paul | 卖出 (S) | Common Stock | 4,643 | USD 92.21 | USD 428,131 | SEC 申报 ↗ |
| 2026-05-15 | German Christopher Paul | 期权行权／转换 (M) | Common Stock | 4,442 | USD 42.17 | USD 187,313 | SEC 申报 ↗ |
| 2026-04-01 | Mazabraud Yann | 期权行权／转换 (M) | Common Stock | 12,875 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-12 | Mathers Edward T | J (J) | Common Stock | 4,199 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-04 | German Christopher Paul | 卖出 (S) | Common Stock | 5,614 | USD 89.56 | USD 502,790 | SEC 申报 ↗ |
| 2026-03-04 | German Christopher Paul | 期权行权／转换 (M) | Common Stock | 1,500 | USD 17.97 | USD 26,955 | SEC 申报 ↗ |
| 2026-03-02 | Mathers Edward T | J (J) | Common Stock | 4,198 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-02 | Smith Hunter C | 期权行权／转换 (M) | Common Stock | 6,099 | USD 6.80 | USD 41,473 | SEC 申报 ↗ |
| 2026-03-01 | German Christopher Paul | 期权行权／转换 (M) | Common Stock | 1,162 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | RYTM |
| CIK | 0001649904 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 487 transaction lines from 2020-01-08 to 2026-09-14 1 P purchase lines · 269 S sale lines · 217 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.